La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Telo Genomics Gestione

Gestione criteri di controllo 4/4

Telo Genomics' Il CEO è Sabine Mai, nominato in Dec2023, ha un mandato di meno di un anno. possiede direttamente 3.77% delle azioni della società, per un valore di CA$ 590.19K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 4.5 anni.

Informazioni chiave

Sabine Mai

Amministratore delegato

CA$30.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	3.8%
Durata media del management	3.4yrs
Durata media del Consiglio di amministrazione	4.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Sabine Mai

less than a year

Mandato

CA$30,000

Compensazione

Dr. Sabine Mai, Ph. D. is CEO at Telo Genomics Corp since 2023 and currently serves as its Interim CEO since 2024 and previously was its Interim CEO since December 2023. She is Chair of Clinical & Scientif...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Sabine Mai	Founder	less than a year	CA$30.00k	3.77% CA$ 421.6k
Sherif Louis	President & CTO	6yrs	CA$231.51k	1.94% CA$ 217.5k
Christopher Ross	Chief Financial Officer	3.4yrs	CA$67.50k	Nessun dato

3.4yrs

Durata media

Gestione esperta: Il team dirigenziale di TELO è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Sabine Mai	Founder	8yrs	CA$30.00k	3.77% CA$ 421.6k
Kenneth Anderson	Member of Clinical & Scientific Advisory Board	7.8yrs	Nessun dato	Nessun dato
William Meekison	Independent Director	4.6yrs	CA$18.00k	0.040% CA$ 4.5k
Ronald McGlennen	Independent Director	2.6yrs	CA$41.06k	Nessun dato
Richard Bender	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Guido Baechler	Independent Chairman of the Board	5.6yrs	CA$82.12k	Nessun dato
Shaji K. Kumar	Member of Clinical Advisory Board	less than a year	Nessun dato	Nessun dato
David Samuel Siegel	Member of Clinical Advisory Board	less than a year	Nessun dato	Nessun dato
Hugh A. Rogers	Independent Director	6yrs	Nessun dato	1.42% CA$ 159.4k
James Berenson	Member of Clinical Advisory Board	less than a year	Nessun dato	Nessun dato
Hans Knecht	Member of Clinical & Scientific Advisory Board	7.8yrs	Nessun dato	Nessun dato
Ivan Borrello	Member of Clinical Advisory Board	less than a year	Nessun dato	Nessun dato

4.6yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TELO sono considerati esperti (durata media dell'incarico 4.5 anni).

Telo Genomics Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Telo Genomics Corp., Annual General Meeting, Nov 27, 2024

High number of new and inexperienced directors

Telo Genomics Corp. Announces Executive Changes

Telo Genomics Corp., Annual General Meeting, Nov 30, 2023

Telo Genomics Corp Announces Chief Executive Officer Changes

Telo Genomics Corp. Appoints Richard A. Bender to Establish and Chair its MM Clinical Advisory Board

Recent updates

Telo Genomics Corp., Annual General Meeting, Nov 27, 2024

Telo Genomics Corp. Evaluates Minimal Residual Disease Biomarker Assay Technologies in Multiple Myeloma Patients as Part of the TELO-MRD Clinical Validation Study

New minor risk - Shareholder dilution

Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic Tests

Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in funding

High number of new and inexperienced directors

New major risk - Share price stability

Telo Genomics Corp. Announces Executive Changes

New major risk - Market cap size

New major risk - Revenue and earnings growth

New major risk - Financial position

Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone Achieved

Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting

Telo Genomics Corp., Annual General Meeting, Nov 30, 2023

New minor risk - Shareholder dilution

Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding

Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding

Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023

Telo Genomics Corp. announced that it expects to receive CAD 2 million in funding

Telo Genomics' Multiple Myeloma Drug Resistance Study Results Selected for Presentation At the 2023 European Hematology Congress

Telo Genomics Corp Announces Chief Executive Officer Changes

Telo Genomics Corp. Launches A Minimal Residual Disease Clinical Trial in Multiple Myeloma

Telo Genomics Corp. Appoints Richard A. Bender to Establish and Chair its MM Clinical Advisory Board

Telo Genomics Corp., Annual General Meeting, Dec 01, 2022

Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples

Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma

Telo Genomics Corp. Completes the Validation of Suite of Proprietary Automation Tools

Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test

Telo Genomics Corp. Appoints Ron McGlennen as Board of Director

Telo Genomics Corp. Advances Its Lead Product and Implements Automation to Its Workflow

Independent Director exercised options to buy CA$102k worth of stock.

Telo Genomics Corp. announced that it has received CAD 2.28775 million in funding

Telo Genomics Corp. announced that it expects to receive CAD 1.5 million in funding

New 90-day high: CA$0.94

Telo Genomics Appoints Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy

New 90-day high: CA$0.54

Telo Genomics Corp., Annual General Meeting, Mar 04, 2021

New 90-day high: CA$0.27

Telo Genomics Corp. Announces the Positive Results of Its Smoldering Multiple Myeloma Proof of Concept Study

Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’S Disease

Telo Genomics Corp. Announces That Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within Ash 2020 Proceedings

New 90-day low: CA$0.20

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media